MTX and ETN Personal non-commercial use only by MD T Kasama & MD S Shiozawa
1Kameda, et al: MTX and ETN
Personal non-commercial use only. The Journal of Rheumatology Copyright © 2011. All rights reserved.
Continuation of Methotrexate Resulted in Better
Clinical and Radiographic Outcomes Than
Discontinuation upon Starting Etanercept in Patients
with Rheumatoid Arthritis: 52-week Results from the
JESMR Study
HIDETO KAMEDA, KATSUAKI KANBE, ERI SATO, YUKITAKA UEKI, KAZUYOSHI SAITO, SHOUHEI NAGAOKA,
TOSHIHIKO HIDAKA, TATSUYA ATSUMI, MICHISHI TSUKANO, TSUYOSHI KASAMA, SHUNICHI SHIOZAWA,
YOSHIYA TANAKA, HISASHI YAMANAKA, and TSUTOMU TAKEUCHI 
ABSTRACT. Objective. The aim of the Efficacy and Safety of Etanercept on Active Rheumatoid Arthritis Despite
Methotrexate Therapy in Japan (JESMR) study is to compare the efficacy of continuation versus dis-
continuation of methotrexate (MTX) when starting etanercept (ETN) in patients with active rheumatoid
arthritis (RA).
Methods. In total, 151 patients with active RA who had been taking MTX were randomized to either
ETN 25 mg twice a week with 6–8 mg/week MTX (the E+M group), or ETN alone (the E group). The
primary endpoint at Week 52 was the radiographic progression assessed by van der Heijde-modified
Sharp score.
Results. The mean progression in total score at Week 52 was not significantly different, statistically,
between the E+M group and the E group (0.8 vs 3.6, respectively; p = 0.06). However, a significant dif-
ference was observed in radiographic progression between Weeks 24 and 52 (0.3 vs 2.5; p = 0.03), and
the mean progression of the erosion score was negative in the E+M group, which was significantly bet-
ter than the E group at Week 52 (–0.2 vs 1.8; p = 0.02). Clinically, the cumulative probability plot of
the American College of Rheumatology (ACR)-N values at Week 52 clearly demonstrated a superior
response in the E+M group than in the E group. ACR20, 50, and 70 response rates at Week 52 in the
E+M group (86.3%, 76.7%, and 50.7%) were significantly greater than those in the E group (63.8%; 
p = 0.003, 43.5%; p < 0.0001 and 29.0%; p = 0.01, respectively).
Conclusion. MTX should be continued when starting ETN in patients with active RA.
(ClinicalTrials.gov: NCT00688103) (J Rheumatol First Release May 15 2011; doi:10.3899/
jrheum.110014)
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The introduction of biological agents such as tumor necrosis
factor-α (TNF-α) inhibitors into the therapeutic strategy for
rheumatoid arthritis (RA) resulted in a shift characterized by
the sufficient inhibition of arthritic signs and symptoms, radi-
ographic progression, and functional disability1,2. However,
the optimal use of those agents remains to be determined. For
example, etanercept (ETN) has been shown to be effective for
RA both as a monotherapy and as combination therapy with
methotrexate (MTX), and the latter has proved its superiority
to the former in MTX-naive patients. Because MTX is the
first-line drug for most patients with RA, and ETN is much
more expensive than MTX, ETN tends to be started for 
MTX-refractory, but not MTX-naive, patients in actual clini-
cal practice3,4.
The Add Enbrel or Replace Methotrexate (ADORE) trial
was the first to consider whether adding ETN to MTX is bet-
ter than replacing MTX with ETN. The trial failed to demon-
strate the superiority of continuing MTX rather than discon-
tinuing it upon starting ETN therapy5. Because the ADORE
trial was only 16 weeks, with a regimen of MTX tapering over
the initial 4 weeks, there could be no marked difference
between continuation versus discontinuation of MTX, if any
difference at all. Longterm efficacy and safety was not com-
pared between the 2 groups.
Therefore, we conducted the Efficacy and Safety of
Etanercept on Active Rheumatoid Arthritis Despite
Methotrexate Therapy in Japan (JESMR) study to address the
differences in clinical activity, radiographic progression, and
functional disability over 2 years. The 24-week results from
the JESMR study demonstrated that continuation of MTX
after the start of ETN was better than discontinuation of MTX,
in terms of European League Against Rheumatism (EULAR)
response and American College of Rheumatology (ACR20)
response rates6. We report the 52-week results, focusing on
the radiographic progression measured by van der
Heijde-modified Sharp (vdH-Sharp) score (which had been
included in the co-primary endpoint), the ACR response7, and
functional disability evaluated by the Health Assessment
Questionnaire-Disability Index (HAQ-DI)8.
MATERIALS AND METHODS
Patients. Our prospective, randomized, open-label study was conducted at 45
institutions in Japan between June 2005 and January 2007. The study proto-
col (ClinicalTrials.gov: NCT00688103) was approved by an institutional
ethics committee of each participating institute. All patients provided written
informed consent in accord with the Declaration of Helsinki.
Patients had to be at least 18 years of age, had to fulfill the ACR 1987
revised classification criteria for RA, and had to meet the guidelines for the
proper use of ETN in Japan [having at least 6 tender joints and 6 swollen
joints, and either a serum C-reactive protein level of > 2 mg/dl or erythrocyte
sedimentation rate (ESR) ≥ 28 mm at 1 h, with adequate safety profiles]9.
Precise inclusion and exclusion criteria have been reported6.
Baseline characteristics of the patients were comparable between the ETN
group (E group) and the ETN + MTX group (E+M group)6. More than 80%
of the patients were women, at an average age of around 57 years, and with a
disease duration of around 9 years (Table 1).
The rheumatoid factor was positive in about 90% of patients. The mean
MTX dose at enrollment was 7 mg/week, with supplementary folic acid in
38%–52% of patients6. The baseline total vdH-Sharp score and its estimated
yearly progression at study entry were very high in both groups, indicating the
severity of disease of our patients (Table 1).
Procedures. Patients who had agreed to receive ETN for active RA were ran-
domly assigned to continue MTX (6–8 mg/wk, an approved dose in Japan
during the study period), that is, MTX + ETN combination therapy, or to dis-
continue MTX and switch to ETN monotherapy. Enrollment and randomiza-
tion were performed on the University Hospital Medical Information
Network Website (Tokyo, Japan) on the day of obtaining informed consent.
Between June 2005 and January 2007, a total of 151 patients from 34 insti-
tutes in Japan were enrolled in the JESMR study. All patients enrolled were
treated with ETN 25 mg as a subcutaneous injection twice weekly.
The co-primary endpoints of the JESMR study showed a good response
according to the EULAR criteria, as based on a 28-joint Disease Activity
Score (DAS28) and the ACR50 response rate at Week 24, as reported6, and
the radiographic progression assessed by vdH-Sharp score ranged from 0 to
448 over 52 weeks10. Two trained readers independently scored each radi-
ograph of hands and feet at baseline and at Weeks 24 and 52. Patient identi-
ties and treatment groups were blinded to the readers, although the chrono-
logical sequence of the radiographs in sets was unmasked. The smallest
detectable difference between readers at baseline was 9.9 (standard deviation
of the per-patient difference between the readers divided by the square root of
2), and the smallest detectable change over 52 weeks was 1.9.
Statistical analysis. A sample size of 150 patients per treatment group was
first calculated to provide > 90% power (α = 0.05, ß = 0.1) with 15% non-
completion rate during 24 weeks. This calculation assumed that the ACR50
response rate would be 40% in the E group and 60% in the E+M group.
However, because of the delay in patient recruitment, we completed the
patient enrollment in January 2005 at a total of 151 patients (74 in the E group
and 77 in the E+M group). This decision was based on the calculation that a
sample size of 64 per treatment group was needed to provide more than 90%
power (α = 0.05, ß = 0.1), assuming that the mean radiographic progression
by vdH-Sharp score at 52 weeks would be 1.50 in the E group and –0.80 in
the E+M group.
Efficacy analyses included all patients who took the study drugs and had
a valid baseline and ≥ 1 on-therapy value for each endpoint. The last obser-
vation carried forward (LOCF) and linear imputation were used for the analy-
sis of clinical and radiographic efficacy, respectively, for missing data. All
analyses were performed by the CMIC Co. Ltd. Data Center (Osaka, Japan).
The proportions of participants who met given criteria were compared with
Fisher’s exact test, while the mean values between the groups were compared
with the Mann-Whitney U test.
RESULTS
Primary endpoint: radiographic efficacy. Efficacy analysis
was performed in 69 patients of the E group and 73 of the
E+M group (Figure 1). The rate of per-protocol patients was
smaller in the E group than in the E+M group, chiefly because
of a lack of efficacy after 24 weeks.
The baseline vdH-Sharp score was 114.5 ± 85.7 in the E
group and 113.1 ± 85.6 in the E+M group (p = 0.99).
Cumulative probability plot analysis suggested less overall
radiographic progression in the E+M group than in the E
group during the 52 weeks (Figure 2A). However, the primary
endpoint at 52 weeks was not met because the numerical supe-
riority of the E+M group over the E group in the change in
vdH-Sharp score over 52 weeks did not reach a statistically
significant difference (0.8 vs 3.6, respectively; p = 0.06), as
shown in Figure 2B. Nonetheless, the mean progression in the
erosion score was negative exclusively in the E+M group, at
2 The Journal of Rheumatology 2011; 38:8; doi:10.3899/jrheum.110014 
Personal non-commercial use only. The Journal of Rheumatology Copyright © 2011. All rights reserved.
both 24 weeks and 52 weeks (–0.1 and –0.2, respectively), and
it was significantly better than that in the E group at 52 weeks
(1.8; p = 0.02). Moreover, a significant difference was
observed in the total score progression between Weeks 24 and
52 (2.5 in the E group and 0.3 in the E+M group; p = 0.03),
suggesting the carrying-over effect of MTX for the initial few
months.
The proportion of patients showing no radiographic pro-
gression over 52 weeks (change in vdH-Sharp score ≤ 0.5)
was 39.6% in the E group and 57.4% in the E+M group (p =
0.07), and the proportion showing no clinically significant
radiographic progression (change in vdH-Sharp score ≤ small-
est detectable change) was 58.5% in the E group and 67.6% in
the E+M group (p = 0.34).
Clinical efficacy. Next we performed for the first time a
cumulative probability plot analysis of ACR-N values at 52
weeks for both treatment groups (Figure 3). This analysis
clearly demonstrated the superior clinical response in the
E+M group compared to the E group, and implied that the
continuation of MTX would be beneficial, at least to some
extent, in nearly 80% of patients upon the commencement of
ETN. Indeed, the mean ± SD of ACR-N was 60.9 ± 29.3 for
the E+M group, which was significantly greater than that of
the E group (31.1 ± 50.8; p = 0.0003). In addition, the area
under the curve of the ACR-N throughout 52 weeks was also
significantly different between the groups (26.8 ± 13.0 in the
E+M group and 18.4 ± 19.0 in the E group; p = 0.008). At the
same time, we could easily see the superior ACR response
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Table 1. Demographic features of the patients. Except where indicated otherwise, values are mean ± SD.
Characteristics ETN, n = 71 ETN + MTX, n = 76 p
Age, yrs 58.1 ± 12.6 56.6 ± 11.1 0.23
Women, % 87.3 80.3 0.27
Body weight, kg 51.0 ± 8.4 54.6 ± 11.3 0.057
Disease duration, yrs 10.6 ± 10.5 8.0 ± 7.6 0.21
Positive rheumatoid factor, % 91.5 86.7 0.43
MTX dose, mg/wk 7.0 ± 1.4 7.4 ± 1.1 0.099
Total vdH-Sharp score, (median; IQR) 114.5 ± 85.7 (94.5; 120.0) 113.1 ± 85.6 (89.5; 91.0) 0.99
Estimated yearly progression, (median; IQR) 17.7 ± 13.2 (13.9; 16.0) 20.8 ± 18.2 (4.4; 12.2) 0.45
Erosion score, (median; IQR) 55.6 ± 53.0 (43.5; 59.5) 56.6 ± 54.4 (37.8; 53.0) 0.80
Joint space narrowing score, (median; IQR) 58.9 ± 33.9 (54.0; 55.0) 56.5 ± 32.9 (47.8; 41.4) 0.79
ETN: etanercept; MTX: methotrexate; vdH: van der Heijde; IQR: interquartile range.
Figure 1. Disposition of patients during 52 weeks of the Efficacy and Safety of Etanercept on Active Rheumatoid Arthritis
Despite Methotrexate Therapy in Japan (JESMR) study. A total of 151 patients were enrolled, 74 in the etanercept (ETN)
group and 77 in the etanercept and methotrexate (MTX) group, and 108 patients (71.5%) completed 52 weeks per protocol. 
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Figure 2. Change in van der Heijde-modified Sharp (vdH-Sharp) total score represented by cumulative probability plot (A) and the mean
change of total score as well as erosion and joint space narrowing scores (B) over 52 weeks. Values are mean ± SEM, compared by Mann-
Whitney U test (*p = 0.03; **p = 0.02) between groups. ETN: etanercept group; ETN+MTX: etanercept plus methotrexate group.
rates in the E+M group compared to the E group, as shown in
Figure 3: 86.3% vs 63.8% in ACR20 (p = 0.003), 76.7% vs
43.5% in ACR50 (p < 0.0001), and 50.7% vs 29.0% in ACR70
(p = 0.01), respectively (Table 2). Except for patient global
assessment, all important clinical measures, including HAQ-
DI, favored the continuation of MTX at Week 52, as shown in
Table 2.
Safety analyses. Safety profiles between the 2 treatment
groups were comparable (Table 3). Similar overall adverse
events were observed between the treatment groups. The fre-
quency of general disorders and administration site condi-
tions, mostly injection site reaction (13 in the E group and 7
in the E+M group), tended to be higher in the E group than the
E+M group, as well as skin and subcutaneous tissue disorders
5Kameda, et al: MTX and ETN
Personal non-commercial use only. The Journal of Rheumatology Copyright © 2011. All rights reserved.
Figure 3. American College of Rheumatology (ACR) values at 52 weeks; 69 patients in the etanercept group (ETN) and 73 in
the etanercept plus methotrexate group (ETN+MTX) were analyzed. Broken lines indicate ACR20, ACR50, and ACR70
 values.
Table 2. Comparison of the clinical responses between treatment groups. Except where indicated otherwise, values are mean ± SD.
Measures ETN, n = 69 MTX + ETN, n = 73 p at 52 Weeks
0 Week 52 Weeks p 0 Week 52 Weeks p Between Groups
Tender joint count (68 assessed) 15.0 ± 9.4 4.3 ± 5.3 < 0.0001 15.1 ± 8.1 2.1 ± 2.8 < 0.0001 0.020
Swollen joint count (66 assessed) 12.4 ± 6.1 4.0 ± 4.4 < 0.0001 12.5 ± 6.5 1.8 ± 2.3 < 0.0001 0.008
Patient global assessment 62.5 ± 20.5 27.4 ± 25.1 < 0.0001 53.7 ± 23.7* 21.3 ± 19.4 < 0.0001 0.264
ESR, mm/l h 59.7 ± 28.4 43.7 ± 27.0 < 0.0001 59.5 ± 26.5 28.9 ± 23.8 0.0002 0.0002
CRP, mg/dl 2.5 ± 2.5 1.3 ± 1.6 < 0.0001 3.0 ± 3.2 0.5 ± 0.8 < 0.0001 0.0003
DAS28 6.1 ± 0.9 4.2 ± 1.5 < 0.0001 6.0 ± 1.0 3.0 ± 1.0 < 0.0001 < 0.0001
EULAR good response, % — 33.3 — — 52.1 — < 0.0001
DAS28 < 2.6, % 0 18.8 — 0 35.6 — 0.038
ACR20 responder, % — 63.8 — — 86.3 — 0.0003
ACR50 responder, % — 43.5 — — 76.7 — < 0.0001
ACR70 responder, % — 29 — — 50.7 — 0.001
HAQ-DI 1.3 ± 0.8 0.9 ± 0.7 < 0.0001 1.2 ± 0.7 0.6 ± 0.6 < 0.0001 0.041
* A significant difference between groups was observed at Week 0 (about 4 weeks after enrollment shown in Table 1) for patient’s global assessment value,
in which p value was 0.025. ETN: etanercept; MTX: methotrexate; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; DAS28: 28-joint Disease
Activity Score; EULAR: European League Against Rheumatism; ACR: American College of Rheumatology; HAQ-DI: Health Assessment Question -
naire-Disability Index.
including eczema and erythema developed at sites unrelated
to ETN injection. In contrast, the frequency of hepatobiliary
disorders, mostly liver dysfunction, tended to be higher in the
E+M group than in the E group. The result was the same
between the groups with metabolism and nutrition disorders
such as hyperlipidemia, diabetes mellitus, and hyperuricemia.
Serious adverse events in the E group were bone fractures in
2 patients (humeral bone and osteoporotic vertebrae). Serious
adverse events in the E+M group were bone fractures in 3
(femoral bone in 2, cranial bone in 1), and in 1 patient each,
congestive heart failure, cellulitis, herpes zoster, brain hemor-
rhage, and mammary carcinoma. Cranial bone fracture from a
traffic accident and cellulitis developed in the same patient.
Treatment was withdrawn because of injection site reaction in
4 patients in the E group and mammary carcinoma in 1 patient
in the E+M group. Thus, the safety profile was comparable
between 2 groups.
DISCUSSION
In a previous report on the 24-week results of the JESMR
study, the superiority of a continuation of MTX over its dis-
continuation when starting ETN in terms of controlling clini-
cal disease activity (the rates of EULAR good response,
remission, and ACR20 response, but not ACR50 and 70
responses) was indicated6. Our 52-week results not only con-
firmed the previous ones but also proved, for the first time,
that the combination of ETN and MTX resulted in a better
outcome in radiographic progression determined by vdH-
Sharp score, especially in erosions, even in patients who had
shown an incomplete response to MTX. The mean progres-
sion in total score at Week 52 was not significantly different,
statistically, between the E+M group and the E group (0.8 vs
3.6, respectively; p = 0.06). The chief reason for failure to
achieve the primary endpoint seemed to be the reduction in
sample size due to delayed recruitment of patients. However,
a significant difference was observed in radiographic progres-
sion between Weeks 24 and 52 (0.3 vs 2.5, respectively; p =
0.03), and the mean progression of the erosion score was neg-
ative in the E+M group, which was significantly better than
the E group at Week 52 (–0.2 vs 1.8, respectively; p = 0.02).
Further, all important clinical measures, including ACR
responses, EULAR responses, and HAQ-DI, favored the con-
tinuation of MTX at Week 52.
Infliximab was the first biological agent to have demon-
strated complete inhibition of radiographic progression in
combination with MTX in MTX-refractory patients with
active RA11. ETN and adalimumab showed similar efficacy in
halting joint destruction in combination with MTX. Both
agents proved their superior clinical and radiographic efficacy
with MTX combination over monotherapy in MTX-naive
patients with early RA (the PREMIER study12) or established
RA (the TEMPO study13). Our results led to the conclusion
that anti-TNF biological agents should be used in combination
with MTX as far as possible, whether the patients are MTX-
naive or MTX-refractory, and they strongly support the recent
recommendations of the ACR3 and EULAR4.
The reason that the continuation of MTX, which had only
shown an inadequate response in the enrolled patients,
demonstrated a significant effect with ETN treatment may be
as follows: (1) the efficacy of MTX was insufficient but not
negligible even as a monotherapy; and (2) the targets of MTX,
including activated T cells14, are not identical to those of
ETN, resulting in additive or synergistic effects between MTX
6 The Journal of Rheumatology 2011; 38:8; doi:10.3899/jrheum.110014 
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Table 3. Adverse events. Values are numbers of patients who developed (serious) adverse events.
Type of Adverse Event ETN, ETN + MTX, p
n = 71 n = 76
Blood and lymphatic system disorders 2 0 0.232
Cardiac disorders 0 1 (1) 1.000
Eye disorders 1 2 1.000
Gastrointestinal disorders 7 5 0.554
General disorders and administration site conditions 15 7 0.063
Hepatobiliary disorders 1 5 0.211
Infections and infestations 19 21 (2) 1.000
Injury, poisoning, procedural complications 3 (2) 5 (3) 0.720
Metabolism and nutrition disorders 1 2 1.000
Musculoskeletal and connective tissue disorders 2 0 0.232
Neoplasms benign, malignant, unspecified 0 1 (1) 1.000
Nervous system disorders 2 4 (1) 0.682
Psychiatric disorders 3 3 1.000
Renal and urinary disorders 0 1 1.000
Reproductive system and breast disorders 0 1 1.000
Respiratory, thoracic, mediastinal disorders 3 2 0.673
Skin and subcutaneous tissue disorders 11 5 0.112
Vascular disorders 1 0 0.483
Serious adverse events 2 7 0.168
ETN: etanercept; MTX: methotrexate.
and ETN. A recent report from the GO-FORWARD study also
demonstrated a better clinical response to golimumab with
MTX continuation than with its discontinuation in MTX-
refractory patients with RA15. The fact that many clinical
(ACR50 and 70 response rates and HAQ-DI score) and radi-
ographic (erosion score progression) measures showed statis-
tically significant differences at Week 52 but not at Week 246
may explain why the ADORE study did not show a difference
between MTX continuation and discontinuation5,16. The use-
fulness of MTX continuation seems to be true with all biolog-
ical agents targeting TNF.
The average disease duration of about 9 years significant-
ly affected the radiographic and HAQ-DI results in the
JESMR study. Despite a long disease duration, our patients
showed a rapid progression in vdH-Sharp scores with a mean
estimated yearly progression of 18–21 (Table 1). This result
was close to that of patients with early active RA who were
enrolled in the PREMIER study (26–27)12 and was much
higher than that in the TEMPO study (8–11)13. This fact may
explain, at least in part, the similarities and differences in the
radiographic progression results among those clinical trials. In
addition, the radiographic progression in our patients could be
more aggressive in the initial few years after disease onset.
Therefore, whether our results are also true for patients with
early RA of < 6 months’ duration should be examined in the
near future. 
Most of the adverse events, including infections and skin
disorders other than injection site reactions, were observed
throughout 52 weeks. However, as expected, injection site
reaction was less frequent after 24 weeks when compared to
our previous report6. In contrast, most of the bone fractures,
which were the predominant serious adverse events in our
study, developed after 24 weeks. This could be attributed at
least in part to the improved activity of daily life of our
patients treated with ETN as demonstrated by the HAQ-DI
improvement (Table 2).
Our study has several limitations. First, it was not double-
blinded. Therefore, one may assume there was an awareness
of the treatment effect evaluations by physicians and by
patients. However, the changes in acute-phase reactants
(Table 2) and radiographic results (Figures 2A and 2B) make
that unlikely. Further, there were considerable withdrawal
rates in the E group (Figure 1), mostly because of a lack of
efficacy after 24 weeks. Since this had been expected, because
this study was not double-blinded, we applied the LOCF
methods for clinical efficacy analyses instead of intention-to-
treat analyses. In addition, the sample size of the JESMR
study limited the power of detection of differences between
the 2 treatment groups. Actual ACR50 response rates and the
radiographic progression were greater than our expectations
in both treatment groups. Finally, the dose of MTX approved
by the Japanese Ministry of Health, Labor and Welfare had
been only 6–8 mg/week throughout this study17,18 although,
concordantly, the use of supplementary folic acid was also
limited to about half of the patients receiving MTX. In
February 2011, the Ministry approved MTX use up to 16
mg/week for patients with RA. Nonetheless, overall clinical
and radiographic outcomes of infliximab added to MTX 7–9
mg/week in Japan19,20,21,22,23 were comparable to those in the
ATTRACT11 and ASPIRE studies24.
Future studies may also include the prediction of patient
outcome after the start of ETN therapy, addressing the ques-
tion of who can be sufficiently controlled by simply switching
from MTX to ETN, and who can be sufficiently controlled by
the addition of ETN to MTX but not by switching from MTX
to ETN. These subanalyses are now under investigation in the
Japan Biological Agent Integrated Consortium (JBASIC)
study group.
Our results demonstrated for the first time that the contin-
uation of MTX resulted in a better clinical and radiographic
outcome, at least in some aspects, than its discontinuation
after the start of ETN in patients with active RA despite MTX
therapy. We also showed the usefulness of cumulative proba-
bility plot presentation not only for radiographic progression
but also for clinical responses such as ACR-N, which may be
included in future clinical trials.
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